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Apoptosis and its dysfunction play a crucial role in different human diseases, such as cancer and neurological degenerative disorders. Cell suicide is regulated by both extra- and intracellular factors that activate conserved cellular processes. The intrinsic pathway involving mitochondria is especially interesting with the participation of molecules both upstream and downstream of the organelle. The complexity of this pathway allows for the strict regulation of cell death and provides the possibility for intervention both at the pre- and post-mitochondrial level.

Proteins of the Bcl-2 family are major determinants of cell viability, controlling the mitochondrial membrane pore formation induced by different death signals converging on the organelle ([@bib5]). Following an increase in the permeability of the outer membrane, cytochrome *c* and other pro-apoptotic proteins are released from the intermembrane space triggering cell demise ([@bib12]). In the cytosol, a complex known as the apoptosome is formed from apoptotic protease activating factor-1 (Apaf-1), procaspase-9, and cytochrome *c*/dATP. *Apaf-1* resembles the *C. elegans* protein CED-4 that is required for apoptosis in the worm ([@bib11]; [@bib23]). Apaf-1 has a caspase recruitment domain (CARD) that allows it to bind to the CARD in caspase 9, a central P loop motif that binds ATP, and at the COOH terminus are WD40 repeats that bind to cytochrome *c* ([Fig. 1](#fig1){ref-type="fig"}). Oligomerization of Apaf-1 leads to autoactivation of procaspase-9 that in turn cleaves caspase-3, ultimately causing cell death ([@bib1]; [@bib10]). The structure of the apoptosome thus constitutes a cellular "death wheel" ([Fig. 1](#fig1){ref-type="fig"}).

Figure 1.**The apoptosome death wheel.** Apaf-1 together with procaspase-9 form the wheel-shaped apoptosome complex. Cytochrome *c* binds to Apaf-1 and drives cell death through the activation of caspase 3. The IAPs, such as XIAP, can counteract caspase activation, but this brake on cell death is diminished by Smac/Diablo released from the mitochondria. The steady-state levels of the various interacting proteins may vary between cell types and with cell differentiation. As well as the apoptosome, other cellular pathways can be activated and probably interact during cell demise.

[@bib20] show that the activity of the apoptosome changes with neuronal differentiation with alterations in both Apaf-1 and the efficacy of the IAPs. IAPs contain one to three well-conserved domains, the so called baculovirus IAP repeats (BIR). Via its BIRs, X chromosome--linked IAP (XIAP) can bind processed caspase-9 and -3, and can in turn be inhibited by proteins, such as Smac/Diablo released from the mitochondria during cell death ([@bib7]; [Fig. 1](#fig1){ref-type="fig"}). Overexpression of XIAP can protect cells against different death stimuli ([@bib15]; [@bib18]), but the role of endogenous IAPs is unclear as neither gene deletion of XIAP or Smac/Diablo showed any abnormality in apoptosis ([@bib9]; [@bib14]).

The biology of the apoptosome has been studied mainly in cell-free systems, and less in living cells. [@bib20] now demonstrate that during differentiation of PC12 cells or primary sympathetic neurons, the level of Apaf-1 is reduced and the protective activities of IAPs are increased. This explains earlier observations that cytoplasmic cytochrome *c* was not able to trigger death of sympathetic neurons, although it was sufficient to kill nonneuronal cells ([@bib6]; [@bib16]). The levels of Apaf-1 are high in nondifferentiated PC-12 cells and sympathetic neurons, but drop dramatically during neuronal differentiation, and this reduction renders the mature neurons resistant to cytochrome *c*--triggered apoptosis. The authors also show that reduction in the level of Apaf-1 is accompanied by increased protection by the IAPs. Although there was no change in the amounts of IAPs or caspase-9, Apaf-1 levels and apoptosome activity were reduced, allowing for more effective regulation by the IAPs. Consistent with this outcome, [@bib19] recently showed that differentiated PC12 cells have increased resistance to cell death that is IAP dependent.

Does this only apply to neuronal cells? [@bib20] show that cytochrome *c* induces rapid caspase activation in the lysates of differentiated primary fibroblasts, as is seen in undifferentiated nerve cells. Thus, in dividing nonneuronal cells, the high Apaf-1 levels keep the activity of the IAPs low. Also, regulation of cell death by the IAPs seems blunted in many mitotic compared with postmitotic cells. In Apaf-1 heterozygous fibroblasts, however, the lowered levels of Apaf-1 enhanced the activity of IAPs, as in the differentiated neurons.

Although the findings refer to postmitotic normal cells, they may have implications for abnormal cells. Small molecular compounds targeting XIAP can lead to activation of caspases and induction of cell death of tumors ([@bib17]). In many cancer cells, the brake exerted by the IAPs is strong enough to counteract cell death. In view of the present findings of a strict correlation between Apaf-1 and the action of XIAP in cell differentiation, it would be interesting to study whether Apaf-1 might be an additional target to consider in cancer therapies. In this case, Apaf-1 may be elevated by enhancing transcription of the gene or possibly by influencing the stability/post-transcriptional modifications of the protein.

Apart from Apaf-1/IAPs, other molecules may influence cell death at the level of the apoptosome. In this respect, a novel factor was recently cloned, named Apaf-1 interacting protein (AIP). It is expressed in brain tissue and is able to protect neurons after ischemia/stroke ([@bib2]). AIP contains only the NH~2~-terminal CARD domain and constitutes a dominant-negative inhibitor of the activity of the Apaf-1--caspase-9 complex. Changes in expression of AIP by cell differentiation or in tumor cells have so far not been reported.

Although there is a partial requirement for Apaf-1 for developmental neuronal apoptosis ([@bib3]; [@bib21]; [@bib4]), loss of Apaf-1 does not prevent all types of cell death, as is evident in lymphoid cells lacking both Apaf-1 and caspase-9 ([@bib13]). In the absence of the apoptosome, apoptosis did not occur in interleukin-3--dependent myeloid cells but the number of cells that eventually died following death stimuli was unaltered ([@bib8]). Deprivation of neurons of trophic factors usually triggers the mitochondrial death pathway and activation of the apoptosome. Differentiated neurons with low levels of Apaf-1 and reduced apoptosome activity die also when challenged by different factors or in neurodegenerative diseases. Whether this still involves Apaf-1--mediated cell death or contributions from other factors is unknown. Cellular pathways, not primarily involving mitochondria and the apoptosome complex, are probably also activated in differentiated brain cells. Thus, sympathetic neurons die through a nonmitochondrial, but still caspase-dependent, pathway in the absence of glial cell line--derived neurotrophic factor ([@bib22]).

In conclusion, [@bib20] reveal many important aspects of neuronal apoptosis, but also raise further questions. It would be interesting to know what makes the IAPs more efficient protectors in the differentiated neurons. Is this achieved by the mere reduction in Apaf-1 levels, or is there a closer association between these proteins in the cell involving some feedback mechanisms? The work nicely connects the regulation of Apaf-1 and the functional state of the IAPs with cell differentiation. However, there is certainly more to be learned about how cell death is regulated in normal, differentiated, and highly proliferating tumor cells. In view of this, the wheel to more insights is still spinning.
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